Results 1 to 10 of about 139,675 (244)

The Role of TIM-3 in Glioblastoma Progression [PDF]

Cells
Several immunoregulatory or immune checkpoint receptors including T cell immunoglobulin and mucin domain 3 (TIM-3) have been implicated in glioblastoma progression.
Farah Ahmady, Amit Sharma, Adrian A. Achuthan, George Kannourakis, Rodney B. Luwor   +4 more
doaj   +4 more sources

Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti–TIM-3 therapy in mice [PDF]

The Journal of Clinical Investigation
Leukemia relapse is a major cause of death after allogeneic hematopoietic cell transplantation (allo-HCT). We tested the potential of targeting T cell (Tc) immunoglobulin and mucin-containing molecule 3 (TIM-3) for improving graft-versus-leukemia (GVL ...
Nana Talvard-Balland, Lukas M. Braun, Karen O. Dixon, Melissa Zwick, Helena Engel, Alina Hartmann, Sandra Duquesne, Livius Penter, Geoffroy Andrieux, Lukas Rindlisbacher, Andrea Acerbis, Jule Ehmann, Christoph Köllerer, Michela Ansuinelli, Andres Rettig, Kevin Moschallski, Petya Apostolova, Tilman Brummer, Anna L. Illert, Markus A. Schramm, Yurong Cheng, Anna Köttgen, Justus Duyster, Hans D. Menssen, Jerome Ritz, Bruce R. Blazar, Melanie Boerries, Annette Schmitt-Gräff, Nurefsan Sariipek, Peter Van Galen, Joerg M. Buescher, Nina Cabezas-Wallscheid, Heike L. Pahl, Erika L. Pearce, Robert J. Soiffer, Catherine J. Wu, Luca Vago, Burkhard Becher, Natalie Köhler, Tobias Wertheimer, Vijay K. Kuchroo, Robert Zeiser   +41 more
doaj   +10 more sources

Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy [PDF]

OncoImmunology, 2018
Both in vivo data in preclinical cancer models and in vitro data with T cells from patients with advanced cancer support a role for Tim-3 blockade in promoting effective anti-tumor immunity.
Catherine A. Sabatos-Peyton, James Nevin, Ansgar Brock, John D. Venable, Dewar J. Tan, Nasim Kassam, Fangmin Xu, John Taraszka, Luke Wesemann, Thomas Pertel, Nandini Acharya, Max Klapholz, Yassaman Etminan, Xiaomo Jiang, Yu-Hwa Huang, Richard S. Blumberg, Vijay K. Kuchroo, Ana C. Anderson   +17 more
doaj   +4 more sources

TIM-3 in Cardiovascular Disease. [PDF]

Curr Heart Fail Rep
PURPOSE OF REVIEW: We summarise the current knowledge of T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) across innate and adaptive immune cells and compile emerging evidence in cardiovascular disease (CVD). RECENT FINDINGS: Immune checkpoints have come to light as potent regulators of immune responses in tumour biology, autoimmune ...
Yousif LI, Sijtema AG, Chevalier MJ, de Boer RA, Meijers WC.   +4 more
europepmc   +4 more sources

TIM-3 expression in breast cancer [PDF]

OncoImmunology, 2018
Tumor-infiltrating lymphocytes (TILs) are predominantly present in breast cancer patients with estrogen receptor negative tumors, among whom increasing levels correlate with favorable outcomes.
Samantha Burugu, Dongxia Gao, Samuel Leung, Stephen K. Chia, Torsten O. Nielsen   +4 more
doaj   +3 more sources

TIM-3 in Leukemia; Immune Response and Beyond [PDF]

Frontiers in Oncology, 2021
T cell immunoglobulin and mucin domain 3 (TIM-3) expression on malignant cells has been reported in some leukemias. In myelodysplastic syndrome (MDS), increased TIM-3 expression on TH1 cells, regulatory T cells, CD8+ T cells, and hematopoietic stem cells
Mahnaz Rezaei, Jiaxiong Tan, Chengwu Zeng, Yangqiu Li, Mazdak Ganjalikhani-Hakemi, Mazdak Ganjalikhani-Hakemi   +5 more
doaj   +3 more sources

The role of the TIM-3 receptor in inflammatory bowel disease and autoimmunity: implications for TIM-3 and TCR crosstalk. [PDF]

J Mol Med (Berl)
Abstract The T cell immunoglobulin and mucin-domain receptor 3 (TIM-3) is an immune checkpoint receptor with complex effects on T cell activation and tolerance. TIM-3 is expressed on the surface of T cells in close proximity to the T cell receptor (TCR), where it mainly acts co-inhibitory, despite lacking typical inhibitory ...
Gabel M, Knauss A, Neurath MF, Weigmann B.   +3 more
europepmc   +4 more sources

Immune checkpoint TIM-3 in tumor immunotherapy. [PDF]

Acta Biochim Biophys Sin (Shanghai)
Over the past decade, immunotherapy has emerged as a pivotal therapeutic strategy in cancer treatment. Immune checkpoint inhibitors (ICIs), such as CTLA-4 and PD-1 monoclonal antibodies, have demonstrated remarkable clinical efficacy in different types of cancer.
Ma S, Zhu M, Ma C, Li C.
europepmc   +3 more sources

Spatial distribution and functional analysis define the action pathway of Tim-3/Tim-3 ligands in tumor development

Molecular Therapy, 2022
The spatial organization of immune cells within the tumor microenvironment (TME) largely determines the anti-tumor immunity and also highly predicts tumor progression and therapeutic response. Tim-3 is a well-accepted immune checkpoint and plays multifaceted immunoregulatory roles via interaction with distinct Tim-3 ligands (Tim-3L), showing great ...
Tixiao Wang
exaly   +3 more sources

TIM-3, a potential target for sepsis therapy. [PDF]

Chin J Traumatol
Immune dysregulation is one of the leading causes of mortality in patients with sepsis. T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), a negative costimulatory molecule, is pivotal for immune regulation during sepsis. The effects of TIM-3 appear to be bidirectional: in the early stages of sepsis, upregulation of TIM-3 may help ...
Huang S, Huang X, Feng X, Wang R, Liao F, Liu D, Sun J, Zhang H, Yu A, Zeng L.   +9 more
europepmc   +3 more sources